Form 8-K · Current Report · Filed 2025-10-30
Edwards Lifesciences Announces CFO Transition Plan
Edwards Lifesciences Corp announced on October 30, 2025, that its CFO, Scott Ullem, plans to transition from his role by mid-year 2026.
- Filer
- Edwards Lifesciences Corporation EW · NYSE
- Filed
- Accession
- 0001193125-25-258662
- CIK
- 0001099800
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The company is initiating a process to appoint a new CFO, and Ullem will continue in an advisory role. This transition aims to ensure continuity and a smooth transfer of responsibilities.
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Regulation FD Disclosure
Market reaction
Close before filing
$82.69
Next session
-0.3%
Since filing
+4.1%
Latest close
$86.07
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from EW reporting the same item, with the next session's move:
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.
Never miss another EW filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.